King County Navigation Bar (text navigation at bottom)
Public Health - Seattle & King County
Site Directory

Public Health Webpage Directory

Public Health Center & Office Locations

For Care Providers

Health Advisories & Resources

For Educators

Health Educators Toolbox

About Us

History & Profile

Jobs

Employee Directory

Contact Us

Public Health
Seattle & King County
401 5th Ave., Suite 1300
Seattle, WA 98104

Click here to email us

Phone: 206-296-4600
TTY Relay: 711

magnifying glass Advanced Search
Search Tips
Home » Epi-Log Newsletter » July 2006

The Epi-Log Newsletter
Volume 46, No. 7 - July 2006

Adobe Acrobat Reader icon This issue is available in Adobe Acrobat PDF format

green square bullet
Outbreak of Vibrio parahæmolyticus Infections Associated with Consumption of Raw Local Oysters
green square bullet

New Recommendations From the Advisory Committee on Immunization Practices

green square bullet

HIV-AIDS Reported Cases for July, 2006

green square bullet
Communicable Disease and Epidemiology contact information
green square bullet Reported Cases of Selected Diseases in Seattle and King County

Outbreak of Vibrio parahæmolyticus Infections Associated with Consumption of Raw Local Oysters

King County and other areas in Washington are experiencing a large outbreak of Vibrio parahæmolyticus infections associated with oyster consumption. Through July 27th, 27 confirmed cases have been reported in King County in 2006, 26 of these reported in July. From 1996 to 2005, 10.6 vibriosis cases, on average, were reported each year (range 4 to 27). Typically, a mean of 2 cases, are reported in July and 4.8 in August (range 1 to 14).

Exercising caution, some restaurants have voluntarily taken raw oysters off of their menus.

Vibriosis is the term used to describe illness caused by infection with V. parahæmolyticus and other non cholera-causing Vibrio species (including non-toxigenic Vibrio cholera). The illness is usually a moderately severe enteritis lasting 1-7 days and characterized by watery diarrhea, abdominal cramps, fever, nausea, vomiting, and headache. Up to 25 percent of cases may develop a dysentery-like syndrome with high fever, bloody or mucoid stools, and elevated WBC. The incubation period is typically 12-24 hours after exposure (range, 4-30 hours). Bacteremia is uncommon, occurring mostly in persons who are immune deficient. Wound infections can occur when broken skin is exposed to warm sea water.

Clinicians should consider V. parahæmolyticus in patients with a compatible clinical syndrome and take a travel and food history including history of eating raw or undercooked seafood, particularly shellfish.  If possible, obtain details related to suspected shellfish consumption, including the location and dates of meals.  As with other enteric infections of public health significance (i.e., E. coli 0157:H7, shigella, salmonella) it is important that clinicians obtain stool cultures to confirm the etiology of infection.  Culture results are important for public health investigations and resulting measures to interrupt transmission.  Please specify on the microbiology lab request that V. parahæmolyticus culture is being requested so that the lab can use the proper selective culture media for vibrios (Typically Thiosulfate Citrate Bile Sucrose Agar or TCBS agar).

V. parahæmolyticus lives worldwide in marine coastal environments. In warm weather, increasing numbers of the organisms multiply in the gut of filter feeding mollusks such as oysters, clams, and mussels. Oysters, commonly eaten raw, are the most common food associated with vibrio infection in the United States . V. parahæmolyticus is killed by cooking to 145ºF.

V. parahæmolyticus infection is not considered particularly communicable, though fecal-oral transmission is theoretically possible. Persons especially susceptible to infection are those with chronic liver disease, decreased gastric acidity, diabetes, peptic ulcer, or immunosuppression. Of the 25 cases reported so far in July 2006, approximately 1/3 reported taking prescription or over-the-counter antacids, H2 blockers, or proton pump inhibitors.

The Washington Food Safety and Shellfish program monitors commercial and recreational shellfish harvest sites for V. parahæmolyticus. Sites where high levels are found are closed for shellfish harvesting. In addition, restaurants and other retail outlets are required to keep shellfish tags identifying the harvest site for every oyster, clam, and mussel they sell. When a confirmed or suspect case of vibriosis is reported, the case is rapidly interviewed by Public Health, and tags from implicated shellfish are retrieved used to identify implicated product and/or growing areas. Since July, multiple growing areas and beaches have been closed for shellfish harvesting in response to the increase in vibrio cases.

Cases of confirmed V. parahæmolyticus should be reported to Public Health during regular work hours at 206-296-4774 or on our 24 hour automated disease report line at 206-296-4782.

New Recommendations From the Advisory Committee on Immunization Practices

New Vaccine to Prevent Cervical Cancer & Genital Warts

In June 2006, the Advisory Committee on Immunization Practices (ACIP), recommended vaccination of girls and young women 9-26 years of age against human papilloma virus (HPV). The American Cancer Society estimates that 9,710 women in the US will be diagnosed with cervical cancer and 3,700 women will die of the disease in 2006. HPV is the sole cause of cervical cancer. The quadravalent vaccine, Gardasil® (Merck), is highly effective against HPV types 16 and 18, responsible for 70% of cervical cancers, as well as HPV types 6 and 11, which cause 90% of genital warts. Gardasil® was licensed by the Food and Drug Administration (FDA) on June 8th, 2006. According to the ACIP, three doses should be routinely given to girls when they are 11 or 12 years old. Vaccination can also be initiated in girls as young as nine years old at the discretion of the health care provider.  The goal is to vaccinate before onset of sexual activity at which time the incidence of HPV infection begins to rise rapidly. Women up to age 26 should be vaccinated because a significant proportion can still be protected against the cancer-causing HPV types though this age.  The vaccine has no effect on established infections and is not a treatment for HPV infection. The vaccine is comprised of recombinant capsid protein from HPV that self-assembles into virus-like particles (VLPs) These particles contain no viral DNA and are therefore non-infectious. More importantly, these particles stimulate the production of antibodies that bind and neutralize the infectious virus. Gardasil® is not yet available through Washington State ’s universal childhood vaccination program because of the time lag between federal approval of a new vaccine and the allocation of funds to purchase the vaccine by the State legislature.

For more information about HPV and Gardasil®, see CDC’s HPV web page at: www.cdc.gov/std/hpv

Second Dose of Varicella Vaccine

ACIP also recommended a second dose of varicella (chickenpox) vaccine for children four to six years old to further improve protection against the disease. The first dose of varicella vaccine is recommended at 12 to 15 months old. Fifteen to 20 percent of children who have received one dose of the vaccine are not fully protected and may develop chickenpox after coming in contact with varicella zoster virus. Additionally, one dose of the vaccine may not continue to provide protection into adulthood when chickenpox is more severe. A second dose of varicella vaccine provides increased protection against varicella disease compared to one-dose. The ACIP also recommended that children, adolescents and adults who previously received one dose should receive a second dose. Until officially authorized by Washington ’s VFC program VFC vaccine should not be used for the newly recommended second dose of varicella.

Both of these recommendations are provisional, and will become official Centers for Disease Control and Prevention (CDC) policy when accepted by the director of CDC and published in CDC’s Morbidity and Mortality Weekly Report (MMWR) – a process that takes an increasingly long time. Accordingly, the ACIP posts their provisional recommendations on their web page at www.cdc.gov/nip/ACIP/default.

HIV-AIDS Reported Cases for July, 2006

Total HIV/AIDS cases reported in this month’s Epi-Log are lower than in the May 2006 issue. In March 2006, Washington transitioned from a name-to-code reporting system to a named HIV reporting system. Since then, HIV data have been accepted into the national HIV/AIDS database at the CDC. In the past, only AIDS data from Washington State were included in the regular national interstate deduplication exercises that ensure that people with HIV/AIDS in the U.S. are counted accurately. Now data about people with HIV or AIDS are included in these exercises. The June 2006 Epi-Log includes the results of an interstate deduplication exercise that for the first time included the records of people with HIV who were not know to have progressed to AIDS. This initial comparison and follow-up resulted in 121 Washington State cases (>66% in King County ) determined to have been originally diagnosed, or having progressed from HIV to AIDS, in another state; consequently they were removed from the case count presented in this report.

Communicable Disease and Epidemiology contact information


Disease reporting
AIDS/HIV 206-296-4645
Sexually Transmitted Diseases 206-744-3954
Tuberculosis 206-744-4579
West Nile virus advisories and resources 206-205-3883
Other Communicable Diseases 206-296-4774
Automated 24-hour reporting line for conditions not immediately notifiable 206-296-4782

Hotlines
Communicable Disease Hotline 206-296-4949
HIV/STD Hotline 206-205-7837

Online
Health Provider homepage
Resources to fact sheets, updated news, vaccine information, health educational materials and external links.

Reported Cases of Selected Diseases in Seattle and King County


.
Cases reported
in June
Cases reported through June
 
2006
2005
2006
2005
Campylobacteriosis
26
36
119
147
Cryptosporidiosis
6
7
15
47
Chlamydial infections
404
580
2,619
2,918
Enterohemorrhagic
E. coli (non-O157)
1
0
1
4
E. coli O157: H7
4
3
10
11
Giardiasis
7
17
56
60
Gonorrhea
170
169
997
830
Hæmophilus influenzæ (cases <6 years of age)
1
1
1
2
Hepatitis A
1
1
6
7
Hepatitis B (acute)
3
2
9
13
Hepatitis B (chronic)
63
54
407
318
Hepatitis C (acute)
1
0
4
4
Hepatitis C (chronic, confirmed/probable)
116
107
737
662
Hepatitis C (chronic, possible)
21
36
157
215
Herpes, genital (primary)
71
157
408
409
HIV and AIDS (includes only AIDS cases not previously reported as HIV)
NA
27
86
220
Measles
0
0
0
0
Meningococcal Disease
1
1
5
11
Mumps
0
0
2
1
Pertussis
5
32
65
134
Rubella
0
0
0
1
Rubella, congenital
0
0
0
0
Salmonellosis
22
24
84
111
Shigellosis
3
4
18
30
Syphilis
14
4
117
70
Syphilis, congenital
0
0
0
0
Syphilis, late
4
7
36
41
Tuberculosis